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Background
We wish to determine the optimal vaccination strategies
for invoking genital tract mucosal immune responses that
might protect against heterosexual HIV-1 transmission.
We therefore conducted a phase 1 trial to determine
whether vaginal immunisation with an HIV-1 envelope
protein could produce genital tract and systemic immune
responses.
Methods
We designed, expressed, and produced under GMP a
trimeric gp140 from a clade C isolate, 96ZM651.8. A
phase 1 trial to establish safety and immunogenicity was
conducted. 100 μg of ZM96gp140 was mixed with 3 ml of
a 0.92% Carbopol® 974P NF polymer gel and delivered
intravaginally 9 times during a single menstrual cycle,
with a 2:1 randomisation of active to placebo. We meas-
ured vaginal, cervical, and systemic IgG and IgA responses
and systemic IFN-gamma ELISpot responses, as well as
safety parameters, with a three month follow up design.
Results
The first female subject was studied with open-label active
immunisation. A total of 22 subjects completed the trial.
There were no serious adverse events (AEs). A variety of
non-serious AEs were recorded. Apart from the first sub-
ject who produced a weak mucosal IgA response to the
trimeric gp140, no other subjects developed anti-
ZM96gp140 responses and none had detectable gp140-
specific, IFN-gamma-secreting peripheral T cells. The
treatment allocations remain blinded at the present time.
Conclusion
We have established the feasibility of conducting phase 1
trials focussing on the measurement of genital tract
responses to mucosal immunisation. We did not find evi-
dence that suggests that vaginal immunisation with an
HIV envelope protein alone can induce robust genital
tract or systemic anti-HIV responses. Future work will
focus on alternative strategies of systemic/mucosal prim-
ing and boosting to determine the optimal immunisation
regimes which can produce robust genital tract and sys-
temic anti-HIV immune responses.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P194 doi:10.1186/1742-4690-6-S3-P194
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P194
© 2009 Lewis et al; licensee BioMed Central Ltd. 